^
    Back
    Association details:
    Biomarker:NPM1-ALK F1174C
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:luminespib (AUY922) (HSP90 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    J Cancer Res Clin Oncol
    Title:

    Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma

    Published date:
    02/08/2014
    Excerpt:
    cDNA sequencing of ALK kinase domain revealed activating mutations—I1171T in Karpas299CR and F1174C in Karpas299CHR....AUY922 potently suppressed growth of Karpas299 parental cells as well as both resistant cell lines, albeit it had slightly weaker effect on Karpas299CHR cells, particularly at a dose of 41 nM (p ≤ 0.001).
    DOI:
    10.1007/s00432-014-1589-3